John Greene, Director at CRISPR Therapeutics AG (CRSP), bought 7,000 shares at $44.85 ($314K) on 2025-02-26, disclosed to the SEC on 2025-02-28.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| Filing → |
| DFS | BUY | 2020-01-27 | $499K | — | Filing → |